Sight Sciences Files 8-K with Financials and Exhibits

TL;DR

SIGHT filed an 8-K with financials and exhibits on 3/27/26.

AI Summary

On March 27, 2026, Sight Sciences, Inc. filed an 8-K report detailing its financial statements and exhibits. The filing includes an iXBRL 8-K document and an exhibit EX-99.1, along with associated XBRL data files. The company's principal executive offices are located at 4040 Campbell Ave, Suite 100, Menlo Park, CA 94025.

Why It Matters

This filing provides updated financial information and exhibits for Sight Sciences, Inc., which is crucial for investors and analysts to assess the company's current financial health and operational status.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and exhibits, not indicating any significant new risks or events.

Key Numbers

• 0001193125-26-130386 — SEC Accession Number (Unique identifier for the filing)

Key Players & Entities

• Sight Sciences, Inc. (company) — Filer
• 0001531177 (company) — CIK
• 2026-03-27 (date) — Period of Report
• 2026-03-30 (date) — Filing Date
• 4040 CAMPBELL AVE, SUITE 100 MENLO PARK CA 94025 (location) — Mailing and Business Address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SGHT The Nasdaq
• $34 m — s; and (ii) awarded monetary damages of $34 million, plus supplemental damages and in

Filing Documents

• sght-20260327.htm (8-K) — 49KB
• sght-ex99_1.htm (EX-99.1) — 28KB
• img169022213_0.jpg (GRAPHIC) — 15KB
• 0001193125-26-130386.txt ( ) — 216KB
• sght-20260327.xsd (EX-101.SCH) — 26KB
• sght-20260327_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 30, 2026, Sight Sciences, Inc. (the "Company") issued a press release announcing that the U.S. District Court for the District of Delaware (the "Court") issued an order preserving the jury's verdict of willful infringement in the patent infringement case (the "Litigation") filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, "Alcon"). The Company had asserted that Alcon's sale of the Hydrus Microstent ("Hydrus") infringed three Sight Sciences patents. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328 (the "Patents"). The Court's order, which was entered on March 27, 2026, (i) preserved the jury's verdict that Alcon willfully infringed all of the Patents; and (ii) awarded monetary damages of $34 million, plus supplemental damages and interest, for past infringement, plus an ongoing royalty of 10% of Hydrus revenue through November 10, 2028, the date of expiration of Sight Sciences' last Patent. A final judgment (the "Final Judgment") is expected to be entered by the Court in the coming months after supplemental damages and pre-judgment interest have been calculated. The Final Judgment is subject to appeal by Alcon. No monetary damages will be recovered by the Company until Alcon exhausts its rights to appeal or the time for filing an appeal has passed. In June 2025, Alcon filed petitions for ex parte reexamination ("EPR") with the U.S. Patent and Trademark Office ("USPTO") challenging the validity of the claims in the Patents that the Company had asserted at trial, based on prior art patents and publications. The USPTO is reexamining the validity of these claims, and any final office actions by the USPTO, if adverse to the Company, are subject to multiple layers of appeal by the Company, initially within the USPTO, and then to the Federal Circuit Court of Appeals. If an adverse, final and non-appealable judgment

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release dated March 30, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sight Sciences, Inc. Date: March 30, 2026 By: /s/ James Rodberg Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR